My cart
In the shopping cart is not goods, to choose and buy!
  • Product Name
  • Size
  • Quantity
  • Amount
    Selected items : 0 pieces Total : CHECK OUT()
    Ampiroxicam (CP 65703)
    Ampiroxicam (CP 65703)

    Market Price:

    This product is for research use only, not for human use. We do not sell to patients.
    Number: - + Pieces(InventoryPieces)
    InvivoChem Cat #: V1070
    CAS #: 99464-64-9Purity ≥98%

    Description: Ampiroxicam (formerly CP 65703; CP65703; CP-65703; Flucam; Ampiroxicamum), a nonsteroidal anti-inflammatory drug (NSAID), is a potent and non-selective inhibitor of cyclooxygenase (COX1/2) enzyme with potential anti-inflammatory activity. It has been approved for use as an anti-inflammatory drug.  

    References: J Natl Cancer Inst. 2006 Jun 21;98(12):855-68; Agents Actions. 1993 Jul;39(3-4):157-65.

    Customer Validation
    Official Supplier of
    • VE
    • OF
    • YALE
    • hhmi
    • 香港大学
    Publications Citing InvivoChem Products
    • Physicochemical and Storage Information
    • Protocol
    • Quality Control Documentation
    • Related Biological Data
    • Customer Review
    Molecular Weight (MW)447.46 
    CAS No.99464-64-9 
    Storage-20℃ for 3 years in powder form
    -80℃ for 2 years in solvent
    Solubility (In vitro)DMSO: 90 mg/mL (201.1 mM)
    Water: <1 mg/mL
    Ethanol: <1 mg/mL
    Other infoChemical Name: Carbonic acid, ethyl 1-((2-methyl-3-((2-pyridinylamino)carbonyl)-2H-1,2-benzothiazin-4-yl)oxy)ethyl ester, S,S-dioxide
    InChi Code: InChI=1S/C20H21N3O7S/c1-4-28-20(25)30-13(2)29-18-14-9-5-6-10-15(14)31(26,27)23(3)17(18)19(24)22-16-11-7-8-12-21-16/h5-13H,4H2,1-3H3,(H,21,22,24)
    SMILES Code: CCOC(=O)OC(C)OC1=C(N(S(=O)(=O)c2c1cccc2)C)C(=O)Nc3ccccn3
    SynonymsCP-65703; Flucam; CP 65703; CP65703; Ampiroxicamum;

    • Molarity Calculator
    • Dilution Calculator
    • The molarity calculator equation

      Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

      • Mass
      • Concentration
      • Volume
      • Molecular Weight *
      • =
      • ×
      • ×
    • The dilution calculator equation

      Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

      This equation is commonly abbreviated as: C1V1 = C2V2

      • Concentration (start)
      • ×
      • Volume (start)
      • =
      • Concentration (final)
      • ×
      • Volume (final)
      • ×
      • =
      • ×
      • C1
      • V1
      • C2
      • V2
    In Vitro

    In vitro activity: Ampiroxicam (<150 μM) dose-dependently decreases the proliferation of Panc-1 cells. Ampiroxicam (50 μM) results in decreased expression of Sp1, Sp3, Sp4, and VEGFR1 proteins in Panc-1 cells and L3.6pl cells as determined by Western blot analysis. Ampiroxicam (50 μM) results in increased phosphorylation of MAPK1/2 in Panc-1 cells and L3.6pl cells.

    Kinase Assay: Panc-1 cells are plated in DME/F12 medium with 5% fetal bovine serum and treated on the next day with vehicle (0.1% DMSO) or various concentrations of Ampiroxicam. Cells are counted at the indicated times with a Coulter Z1 cell counter. Each experiment is done in triplicate, and results are expressed as means, with error bars representing 95% confidence intervals (CIs).

    In VivoAmpiroxicam inhibits the stretching response in mice induced by phenylbenzoquinone (PBQ) with maximum protective effect (MPE) of 2 mg/kg. Ampiroxicam inhibits swelling in a dose-responsive manner in the rat foot edema (RFE) assay with ED50 of 28 mg/kg at single oral dose and 7.8 mg/kg at 5 daily oral dose. Ampiroxicam blocks primary and secondary lesion development in rat adjuvant arthritis with ED50 of 2.2 mg/kg and 0.5 mg/kg, respectively. Ampiroxicam (3.2 mg/kg) leads to a plasma concentration of 12 μg/mL at a Tmax of 2 hours for piroxicam derived from ampiroxicam in rats. Ultraviolet-A (UVA)-irradiated 1% Ampiroxicam sensitized in guinea pigs shows positive reaction in the patch testing to UVA-irradiated 1% Ampiroxicam and 1% thiosalicylate (TOS). Concentration of Ampiroxicam is easily reduced by the increase in UVA irradiation doses, as compared with that of piroxicam. 
    Animal modelRats with adjuvant arthritis 
    Formulation & DosageDissolved in 0.1% methylcellulose; 3.2 mg/kg; p.o.
    ReferencesJ Natl Cancer Inst. 2006 Jun 21;98(12):855-68; Agents Actions. 1993 Jul;39(3-4):157-65.

    These protocols are for reference only. InvivoChem does not independently validate these methods.

    Comparative effects of nonsteroidal antiinflammatory drugs (NSAIDs) on Panc-1 cell proliferation and Sp protein expression. J Natl Cancer Inst. 2006 Jun 21;98(12):855-68.
    Effects of tolfenamic acid and ampiroxicam on pancreatic cancer cell proliferation. J Natl Cancer Inst. 2006 Jun 21;98(12):855-68.
    Inhibition of orthotopic pancreatic tumor growth and angiogenesis in mice by tolfenamic acid and gemcitabine. J Natl Cancer Inst. 2006 Jun 21;98(12):855-68.


      Home Prev Next Last page / pices


      Your information is safe with us. * Required Fields.
      Products are for research use only;  We do not sell to patients
      Tel: 1-708-310-1919
      Fax: 1-708-557-7486
      Subscribe to our E-newsletter
      • Name*
      • *
      • E-mail*
      • *
      • instructions:
      • *
      Copyright 2020 InvivoChem LLC | All Rights Reserved
      Do you confirm the receipt?